Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efpeglenatide - Hanmi Pharmaceutical/Sanofi

Next Previous
X
Search
Drug Profile

Efpeglenatide - Hanmi Pharmaceutical/Sanofi

Alternative Names: HM-11260C; Langlenatide; LAPS-Exd4; LAPS-Exendin; LAPS-exendin 4 analogue; LAPS-Exendin4; LAPSCA-Exendin4; SAR-439977

Latest Information Update: 31 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hanmi Pharmaceutical
  • Developer Hanmi Pharmaceutical; Sanofi
  • Class Antihyperglycaemics; Immunoglobulin Fc fragments; Obesity therapies; Peptides; Polyethylene glycols; Pyrrolidines; Recombinant proteins
  • Mechanism of Action Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Type 2 diabetes mellitus
  • Phase II Obesity

Most Recent Events

  • 31 Jul 2024 Efpeglenatide is still in phase II trials for Obesity in USA, Germany, Hungary, Netherlands, Sweden, Spain (Hanmi Pharmaceutical pipeline, July 2024)
  • 31 Jul 2024 Efpeglenatide is still in phase II trials for Type 2 diabetes mellitus in USA, Germany, Hungary, Spain, Italy, Netherlands (Hanmi Pharmaceutical pipeline, July 2024)
  • 31 Jul 2024 Efpeglenatide is still in phase III trials for Type 2 diabetes mellitus in USA, Canada, Sweden, Argentina, Estonia, Italy, Lithuania, Slovakia, Ukraine, Hungary, Germany, United Kingdom, Poland, Bulgaria, Chile, Denmark, Finland, India, Latvia, Mexico, Norway, Peru, Romania, Russia, Serbia, South Africa, Turkey, Spain, China (Hanmi Pharmaceutical pipeline, July 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top